EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

SillaJen Inc (215600) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of SillaJen Inc KRW 551, price KRW 2,240, upside -75.4%, quality 36 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · KR · ISIN KR7215600008

SI Thin data Sep 24, 2026

SillaJen Inc

215600 · KQ

Weakest SetupStrongly overvalued and low quality.

!Fair value 550.85 KRW · Strongly overvalued (−75%)
!Quality 36/100
!Mixed Growth (revenue 5y +40.8 %/yr)
!Low debt · negative free cash flow
!Trails peers (3/8)
!Narrow moat 16/100
!Evidence only low, so the estimate is less certain
Watch SillaJen Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

74,657 KRW 1,844 KRW Fair Value 550.85 KRW Nov 2018 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range 1,844 KRW – 74,657 KRW · fair‑value band 363.56 KRW – 688.56 KRW · the 2,240 KRW price screens above the 550.85 KRW fair value. Dashed = 300-day average. As of Sep 24, 2026.

Follow SillaJen in your weekly email

Every Wednesday you see whether SillaJen is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

SillaJen, Inc., together with its subsidiaries, engages in developing technologies and products using genetic engineering in South Korea. Its clinical pipeline includes Pexa-Vec, which is in phase 2 clinical trial to treat renal cell carcinoma and prostate cancer, as well as in phase 1 clinical trial to treat melanoma and solid tumors.

Show more

SillaJen, Inc., together with its subsidiaries, engages in developing technologies and products using genetic engineering in South Korea. Its clinical pipeline includes Pexa-Vec, which is in phase 2 clinical trial to treat renal cell carcinoma and prostate cancer, as well as in phase 1 clinical trial to treat melanoma and solid tumors. The company also develops BAL0891, which is in phase 1 clinical trial for the treatment of solid tumors; and SJ-600 Series and JX-970 to treat solid tumors and is in preclinical trial. In addition, it operates in biotechnology research industry. SillaJen, Inc. was founded in 2006 and is headquartered in Seoul, South Korea.

Stock analysis

SillaJen Inc (215600) currently trades at 2,240 KRW, while our model-based Fair Value estimate is 550.85 KRW, implying the stock looks roughly 306.7% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: 363.56 KRW (bear) to 688.56 KRW (bull), the price of 2,240 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 36/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

SillaJen Inc reported revenue of 9.2B KRW in FY2025 versus 254M KRW in FY2021, a compound +145.4%/yr. Reported net income was −24.2B KRW in FY2025.

Key figures

Market cap 309B KRW (≈ $227M) · P/S ratio 26.2 · Net margin −221% · Return on equity −20.8% · Return on assets (EBIT) −21.6% · Operating margin −198% · Revenue (TTM) 10.9B KRW · Revenue growth (YoY) +146%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 37 out of 100 (medium confidence).

What moves the price

The share trades about 55% below its 52-week high and 21% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −75%, 215600 screens richer than that median.

Fair Value models

Bear 363.56 KRW Fair Value 550.85 KRW Bull 688.56 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) 398.62 KRW 534.15 KRW 797.24 KRW 54
All 1 models by family
Asset-Based
NCAV (Graham) 398.62 KRW 534.15 KRW 797.24 KRW 54

Open the full fair value analysis →

Notify me when 215600 reaches fair value

Put 215600 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 36/100

Of which business quality 38 · Market factors (momentum, volatility) 28

Profitability 2
Margins and returns on capital today
Quality Growth 74
Are margins and returns improving?
Cashflow 10
Earnings quality: real cash, not paper profit
Fin. Strength 79
Balance sheet, leverage, solvency risk
Investment 40
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 26
Price trend over the last 3–12 months (market factor)
52W Momentum 7
Distance to the 52-week high (market factor)
Net Issuance 37
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 29/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+134.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+22.5%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+40.8%
Start year 2020 (pandemic). Over 10 years: +17.7% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−2,767.5% (2020) → −285.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

215600 screens 307% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Compare SillaJen Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 654 stocks

Beats the industry median on 3/7 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 38 · Below median
Fair Value upside −75% · Bottom 25%
Profitability
Return on assets −13% · Below median
Operating margin (TTM) −198% · Bottom 25%
Growth and dividend
Revenue growth 146% · Top 25%
Balance sheet
Debt / equity 0.01× · Below median

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/S (TTM) 0.02× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)100 · sector 97
DIVIDEND (yield)0 · sector 23

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX $522.38 $574.62 +10%
Regeneron Pharmaceuticals, Inc REGN $801.82 $1,252 +56%
argenx SE ARGX $963.79 $918.60 −5%
Samsung Biologics Co 207940 1,366,000 KRW 1,502,600 KRW +10%
CSL Limited CSL A$179.12 A$197.03 +10%
Alnylam Pharmaceuticals, Inc ALNY $251.65 $218.36 −13%
Royalty Pharma plc RPRX $58.52 $24.22 −59%
BeOne Medicines AG 6160 HK$218.20 HK$169.72 −22%
Celltrion, Inc 068270 177,400 KRW 74,519 KRW −58%
BioNTech SE BNTX $100.87 $63.62 −37%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

SillaJen Inc · Fair Value
550.85 KRW −307%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "SillaJen Inc Fair Value". https://www.fairvalue-calculator.com/stock/215600

Frequently asked questions

Is SillaJen Inc (215600) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 550.85 KRW versus a price of 2,240 KRW, about −75% upside (overvalued).
What is the fair value of 215600?
Our model-based fair value for SillaJen Inc is 550.85 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 2,240 KRW.
What is the quality score of 215600?
SillaJen Inc has a Quality Score of 36/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for SillaJen Inc (215600)?
Our model-based price target is the fair value of 550.85 KRW (as of Sep 24, 2026) from 1 valuation models. Cautious scenario 363.56 KRW, optimistic scenario 688.56 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the SillaJen Inc stock forecast for 2026?
Our models put fair value at 550.85 KRW, about −75% upside versus a price of 2,240 KRW (overvalued). Cautious scenario 363.56 KRW, optimistic scenario 688.56 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of SillaJen Inc (215600)?
SillaJen Inc reported trailing-twelve-month revenue of about 10.9B KRW (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of SillaJen Inc (215600)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For SillaJen Inc it is 550.85 KRW per share (as of Sep 24, 2026), against a price of 2,240 KRW. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is SillaJen Inc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 215600 trades above its calculated fair value: price 2,240 KRW, fair value 550.85 KRW, a gap of about −75% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 215600?
No. The price is what the market pays today (2,240 KRW); the fair value is what the company's own numbers justify (550.85 KRW). For SillaJen Inc the two are 1,689 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is SillaJen Inc worth?
The market values SillaJen Inc at about 309B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 2,240 KRW; our models calculate a fair value of 550.85 KRW per share.
What do the bullish and bearish scenarios say about 215600?
Our models span a range for SillaJen Inc: cautious scenario 363.56 KRW, base 550.85 KRW, optimistic 688.56 KRW per share (as of Sep 24, 2026, price 2,240 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of SillaJen Inc (215600)?
Balance-sheet figures for SillaJen Inc (as of Sep 24, 2026): return on equity −20.8%, debt of 0.01 per unit of equity. They feed the Quality Score of 36/100, which measures business quality independently of the share price.
How far is 215600 from its 52-week high?
SillaJen Inc trades at 2,240 KRW, about 55% below its 52-week high of 4,975 KRW and 21% above the low of 1,844 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 550.85 KRW is for.
Which stocks are comparable to SillaJen Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is SillaJen Inc stock attractive at the current price?
The data as of Sep 24, 2026: price 2,240 KRW, calculated fair value 550.85 KRW (−75%), Quality Score 36/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 215600 calculated?
We run SillaJen Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 550.85 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. SillaJen Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of SillaJen Inc (215600)?
The closing price on Sep 23, 2026 was 2,240 KRW. Our model-based fair value is 550.85 KRW, about −75% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with SillaJen Inc right now?
The price sits above even our optimistic bull case (688.56 KRW). The favourable scenario is already priced in. Weak quality (36/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (363.56 KRW to 688.56 KRW) leaves room in how you read the outcome.

Key figures of SillaJen Inc

How large is the market capitalisation of SillaJen Inc (215600)?
The market capitalisation of SillaJen Inc is 309B KRW (≈ $227M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of SillaJen Inc (215600)?
The price-to-sales ratio of SillaJen Inc is 26.2 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of SillaJen Inc (215600)?
The net margin of SillaJen Inc is −221% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of SillaJen Inc (215600)?
The return on equity (ROE) of SillaJen Inc is −20.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of SillaJen Inc (215600)?
On an EBIT basis the return on assets of SillaJen Inc is −21.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of SillaJen Inc (215600)?
The operating margin of SillaJen Inc is −198% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at SillaJen Inc (215600)?
Revenue at SillaJen Inc is growing +146% versus a year earlier (3y avg +22.5%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does SillaJen Inc (215600) generate?
The free cash flow of SillaJen Inc is −26.2B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does SillaJen Inc (215600) carry?
The net debt of SillaJen Inc is 1.8B KRW (fiscal year 2022). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch SillaJen Inc in the live analysis

One click puts SillaJen Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.